Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab
/in Clinical Trial, Metastatic, Phase 1/by MaxLYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer
/in Preclinical Research, PROTACs/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 30/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Made it again this week! A small collection of interesting studies, as we wait for ESMO 2025 this coming fall. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]
New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Final PEACE-3 Trial Data: Radium-223 + Enzalutamide Extends Survival by 5.6 Months in Bone mCRPC. March 2, 2026
- Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection March 2, 2026
- Newsletter 9/2026 March 1, 2026
- CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings February 25, 2026